Ernexa
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1035 Cambridge St 18A, Cambridge, Massac...Phone Number
(617) 798-6700Website
www.ernexatx.comRevenue
-Stock Symbol
ERNAIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Ernexa
Ernexa Therapeutics is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexas core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexas allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting. ERNA-101 is the Companys lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The Companys initial focus is to develop ERNA-101 for the treatment of ovarian cancer.Explore more
Ernexa Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ernexa your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Ernexa has recently received funding, and reach out quickly before it becomes old news!
Ernexa, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Ernexa has new funding data
Earning: See what the market has to say on Ernexa recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Ernexa
Product Launch: Get notified when Ernexa launches new products
Check out if Ernexa is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Ernexa had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Ernexa
Find 2 more new buyers
Company Profile Activity
Activity Insights
Ernexa is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ernexa is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ernexa.
Ernexa financials insights
Gather financial insights about Ernexa, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Debt
$15.1M
Private Equity
$40.6M
2016
Multiple Rounds
$41.6M
2020
Debt
$150K
2021
Unspecified
$20M
Stock Offering
$40.7M
2026
Stock/Share Issuance
$10.5M
Ernexa Tech Stack
A closer look at the technologies used by Ernexa
See more technologies
Most Recent Scoops
Person-Based
Executive Move
Executive Moves, Board of Directors
Person-Based
Pharmaceuticals
Person-Based
Medical Research, Pharmaceuticals
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Ernexa News & Media
Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
President and CEO Sanjeev Luther to present on Wednesday, September 16, 2026, at 12:00 p.m. ETErnexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Video webcast now available hereErnexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage
Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governanceErnexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically "Cold" Tumors Into Targets for the Immune System
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Ernexa
Sign Up For FreeTo access detailed company insights
Ernexa Therapeutics is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexas core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexas allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatm... Read More
